Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Oct;40(7):970-973.
doi: 10.1007/s10875-020-00806-6. Epub 2020 Jun 27.

Flow Cytometry Identifies Risk Factors and Dynamic Changes in Patients with COVID-19

Affiliations

Flow Cytometry Identifies Risk Factors and Dynamic Changes in Patients with COVID-19

Daniele Moratto et al. J Clin Immunol. 2020 Oct.
No abstract available

Keywords: COVID-19; T lymphocytes; flow cytometry; monocytes; plasmablasts.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1
Lymphocyte and monocyte phenotype at first evaluation. Comparison of lymphocytes subsets (upper rows) and surface marker expression on monocytes (bottom row) at the time of first evaluation between controls (C) and COVID-19 patients classified as moderate who recovered (M- > R), severe who recovered (S- > R), and severe who progressed to critical status (S- > C). The shaded area represents the range of normal values in controls. **p < 0.01, ***p < 0.001,****p < 0.0001. Pairwise comparisons were made by the Mann-Whitney test with Bonferroni correction, after a significant Kruskal-Wallis test

References

    1. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Zhong NS, China Medical Treatment Expert Group for Covid-19 Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708–1720. doi: 10.1056/NEJMoa2002032. - DOI - PMC - PubMed
    1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506. doi: 10.1016/S0140-6736(20)30183-5. - DOI - PMC - PubMed
    1. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054–1062. doi: 10.1016/S0140-6736(20)30566-3. - DOI - PMC - PubMed
    1. Hadjadj J, Yatim N, Barnabei L, Corneau A, Boussier J, Pere H, et al. Impaired type I interferon activity and exacerbated inflammatory responses in severe Covid-19 patients. medRxiv 2020. 10.1101/2020.04.19.20068015. - PMC - PubMed
    1. Piva S, Filippini M, Turla F, Cattaneo S, Margola A, De Fulviis S, et al. Clinical presentation and initial management critically ill patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in Brescia, Italy. J Crit Care. 2020;58:29–33. doi: 10.1016/j.jcrc.2020.04.004. - DOI - PMC - PubMed

Publication types

MeSH terms

Substances